Esketamine
Active ingredient · 2 therapeutic classes
Sold as Spravato
- Drug class
- Other General Anesthetics
- Availability
- See label
- Routes
- Nasal
- Markets covered
- 3
- Products on record
- 8
Overview
Esketamine is an active pharmaceutical ingredient in the Other General Anesthetics group (N01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | April 24, 2026 |
| EU European Union | EMA | 1 | September 10, 2025 |
| CA Canada | Health Canada | 1 | July 10, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
Induction and maintenance of general anaesthesia, as the only anaesthetic or in combination with another anaesthetic - Anaesthesia and pain relief (analgesia) in emergency medicine - Supplementation of regional or local anaesthesia.
How to take
EUEuropean Union· EMA
1 product
Uses
Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
Spravato, co-administered with oral antidepressant therapy, is indicated in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.
1 for a description of the populations studied.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Esketamine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 246. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL000571497 · revised May 20, 2022
- [2]European Medicines Agency · EMEA/H/C/004535 · revised September 10, 2025
- [3]Health Canada (DPD) · 02499290 · revised July 10, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.